Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma

LESSONS LEARNED. Due to evolving imaging criteria in brain tumors and variation in magnetic resonance imaging evaluation, it is not ideal to use response rate as a primary objective. Future studies involving antiangiogenic agents should use overall survival. Disease‐expected toxicities should be con...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Affronti, Mary Lou, Jackman, Jennifer Gamboa, McSherry, Frances, Herndon, James E., Massey, Elwood C., Lipp, Eric, Desjardins, Annick, Friedman, Henry S., Vlahovic, Gordana, Vredenburgh, James, Peters, Katherine B.
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2018
Assuntos:
Clinical Trial Results
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6156179/
https://ncbi.nlm.nih.gov/pubmed/29666296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0149
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares